表在性膀胱腫瘍に対する各種抗癌剤単剤投与の効果に関する検討 ： 第1報 ： N-butyl-N-(4-hydroxybutyl)nitrosamine(BBN)ラット膀胱腫瘍発育に対する効果について

Abstract

The present investigation was conducted to examine the effects of various chemotherapeutic agents on development of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) in rats. All rats were given 0.05% BBN in drinking water for the initial 8 weeks of the experiment. Chemotherapeutic agents evaluated in this investigation were administered as single treatments during the subsequent 12 weeks and rats were sacrificed after 20 weeks of the experiment. The investigation was divided into 3 experimental groups according to animal strains and administration methods of chemotherapeutic agents : (1) intraperitoneal administration in male Wistar rats ; (2) oral administration in male Fischer 344 rats ; and (3) intraperitoneal administration in male Fischer 344 rats. In experimental group (1), 5-fluorouracil (5-FU), 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207), carboquone (CQ), vincristine (VCR) and cis-diamminedichloroplatinum (CDDP) were effective in suppressing the incidence of bladder tumor. On the other hand, doxorubicin (DXR), mitomycin-C (MMC), neocarcinostatine (NCS), cyclophosphamide (CPM) and bleomycin (BLM) were not effective. In experimental group (2), both UFT, 4:1 mixture of uracil and tegafur, and 1-hexylcarbamoyl-5-fluorouracil (HCFU) suppressed the incidence of bladder tumor. In experimental group (3), N, N', N"-triethylene thiophosphoramide (thiotepa) also suppressed the tumor incidence. These results indicate that 5-FU analogue, CQ, VCR, CDDP and thiotepa may be clinically effective for prophylactic treatment for superficial bladder cancer. In addition, continued use of this murine bladder model is recommended for future screening of chemotherapeutic agents for superficial bladder cancer.